Goldman Sachs raised the firm’s price target on Teva (TEVA) to $35 from $31 and keeps a Buy rating on the shares.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
- Sagimet Biosciences, TAPI announce global license agreement for resmetirom
- Teva price target raised to $35 from $28 at JPMorgan
- Insider Selling Frenzy: AppLovin, Teva, AST SpaceMobile, MongoDB, and Western Digital Stocks in Focus!
- Teva Pharmaceutical Extends Revolving Facility Agreement
- FTC investigation prompts Teva request for removal of patents from Orange Book